We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

By LabMedica International staff writers
Posted on 01 Oct 2024

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. More...

Antigen-based tests provide quicker results but often lack the sensitivity and accuracy of PCR. Now, a new method that combines confocal fluorescence microscopy with microfluidic laminar flow marks a significant advancement in virus detection. Unlike traditional PCR, this innovative approach can rapidly detect individual virus particles cost-effectively, using a 3D-printed microscopy technology called Brick-MIC. This method boosts both sensitivity and specificity in virus detection, potentially transforming how viral outbreaks are monitored and managed. Its portable and user-friendly design makes it well-suited for wider clinical applications, strengthening public health responses to emerging viral challenges.

The breakthrough virus detection method developed by a group of researchers that included scientists from The Hebrew University of Jerusalem (Rehovot, Israel) uses laminar flow in a microfluidic channel along with fluorescence signals from free dyes and labeled antibodies to reveal key characteristics of nanoparticles. The team demonstrated the method's accuracy by testing it on fluorescent beads and various viruses, including the SARS-CoV-2 Spike protein. One of the key elements of this new assay is the use of hydrodynamic focusing, which significantly enhances sensitivity, enabling virus detection at clinically relevant concentrations.

Its portability and the use of the affordable 3D-printed Brick-MIC setup make it accessible for clinical environments. This innovation signals a shift toward rapid and precise virus detection, in line with personalized healthcare principles. By enabling fast, specific identification of viruses, this technology could help tailor medical interventions to individual patient needs, improving the timeliness and effectiveness of treatments. The research was published in iScience, with the 3D-printed microscopy approach detailed in Science Advances.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Drug Testing Assays
Atellica DT 250 Analyzer
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.